Every recall we track for Ascend Laboratories, LLC — 50 in all — plus the complaints and injury reports the public filed about them.
Ascend Laboratories recalls 150mg Dabigatran Etexilate Capsules (60-count) manufactured in India with potential impurities that could affect safety. This is a prescription drug.
Ascend Laboratories recalls 75mg Dabigatran Etexilate Capsules (30-count) with impurity issues that could affect safety. Consumers should check product details and contact the manufacturer.
Ascend Laboratories recalls 75mg Dabigatran Etexilate capsules (NDC 0904-7253-68) due to failed impurity tests. This could affect drug safety for patients using blood thinners.
Ascend Laboratories recalls 10mg/20mg Amlodipine and Olmesartan Medoxomil tablets (NDC 67877-500-30) due to failed dissolution specs causing low drug content. Rx only, manufactured in India, distributed in US.
Ascend Laboratories recalls 110mg Dabigatran etexilate capsules (NDC 0904-7254-68) manufactured by Alkem Laboratories in India. The capsules failed impurity tests, potentially causing safety issues. Consumers should contact the manufacturer for details.
Ascend Laboratories recalls 150mg Dabigatran etexilate capsules (NDC 0904-7255-10) manufactured by Alkem Laboratories in India. The capsules failed impurity tests during stability testing, potentially posing health risks.
Ascend Laboratories recalls 115mg Minocycline Hydrochloride Extended-Release Tablets due to failed dissolution test. This may affect medication effectiveness. Check NDC 67877-644-30 and lot numbers for affected products.
Ascend Laboratories recalls 5mg/40mg Amlodipine and Olmesartan Medoxomil tablets (Rx only) manufactured by Alkem Labs in India. The tablets may have lower than expected drug content, potentially reducing effectiveness for blood pressure control.
Ascend Laboratories recalls 25mg metoprolol succinate extended-release tablets due to failed dissolution specifications. This may affect medication effectiveness. Contact for remedy details.
Ascend Laboratories recalls 40mg Atorvastatin Calcium Tablets (NDC 67877-513-90, 67877-513-05, 67877-513-10) due to failed dissolution specifications. Consumers should contact the manufacturer for details.
Ascend Laboratories recalls 90-count, 500-count, and 1000-count Atorvastatin Calcium 10mg tablets (Rx only) due to failed dissolution specifications. No remedy stated in recall notice.
Ascend Laboratories recalls 20mg Atorvastatin Calcium Tablets with failed dissolution specifications. These tablets may not release medication properly, risking ineffective treatment. Check NDC codes and expiration dates for affected lots.
Ascend Laboratories recalls 80mg Atorvastatin Calcium Tablets (NDC 67877-514-90 and 67877-514-05) with failed dissolution specifications. These prescription statins may not release medication properly, potentially affecting cholesterol control.
Ascend Laboratories recalls 10mg Aripiprazole tablets (NDC 67877-432-03) due to superpotent drug hazard. Rx-only product manufactured in India, distributed in the US. Check your prescription label for recall details.
Ascend Laboratories recalls 30-count 5mg/40mg Amlodipine and Olmesartan Medoxomil tablets (NDC 67877-501-30) manufactured by Alkem Laboratories in India. The tablets may not dissolve properly, potentially affecting medication effectiveness.
Ascend Laboratories recalls 5mg rizatriptan tablets due to potential N-nitroso-dimethyl-rizatriptan impurity above FDA limits. Affected lots manufactured in India, distributed in US. No remedy specified.
Ascend Laboratories recalls 10mg Rizatriptan Benzoate Tablets with N-nitroso-dimethyl-rizatriptan impurity above FDA limits. Affected lots from India manufacturing, distributed in US. No remedy stated in recall notice.
Ascend Laboratories recalls Cephalexin oral suspension with potential impurity issues. Affected lots manufactured by Alkem Laboratories in India. Consumers should check NDC and expiration dates for affected products.
Ascend Laboratories recalls Cephalexin oral suspension due to impurity detected in stability testing. Affected lots expire by 2025-2026. No remedy specified in official notice.
Ascend Laboratories recalls 75mg Dabigatran Etexilate capsules (NDC 67877-474-60) manufactured by Alkem Labs in India. The capsules contain N-nitroso-Dabigatran impurity above safety limits, potentially causing health risks.
Ascend Laboratories recalls 150mg Dabigatran Etexilate capsules (NDC 67877-475-60) due to presence of N-nitroso-Dabigatran impurity above safety limits. Rx only, manufactured in India, distributed in US.
Ascend Laboratories recalls 360 mg Mycophenolic Acid Delayed-Release Tablets due to failed dissolution specifications. This may affect medication effectiveness. Check NDC 67877-427-12 and lot numbers for affected batches.
Ascend Laboratories recalls specific batches of fosfomycin granules for oral solution due to failed impurities testing. This may affect prescription medication safety.
Ascend Laboratories recalls 90-tablet Ibuprofen and Famotidine tablets (Rx only) due to a stray Rasagiline Mesylate tablet found in unopened bottles. No remedy provided in official notice.
Ascend Laboratories recalls Fosfomycin Tromethamine Granules for Oral Solution due to impurities detected after 6 months of storage. Affected lots from June 2024 to September 2024. No remedy specified.
Ascend Laboratories recalls 0.5mg Fingolimod capsules (NDC 67877-476-30) due to failed dissolution specifications. This may affect drug effectiveness.
Ascend Laboratories recalls 20mg Aripiprazole tablets (NDC 67877-434-05) manufactured by Alkem Labs in India. The tablets failed a spectroscopic identification test, potentially affecting drug quality.
Ascend Laboratories recalls 75mg Dabigatran Etexilate capsules with N-nitroso-dabigatran impurities above safe limits. Patients should contact their doctor for guidance.
Ascend Laboratories recalls 150mg Dabigatran Etexilate capsules (NDC 67877-475-60) due to detected N-nitroso-dabigatran impurities exceeding safety limits. Affected lots expire May 2024 or July 2024.
Ascend Laboratories recalls 50mg Metoprolol Succinate Extended-Release Tablets due to failed dissolution specification. This may affect medication effectiveness. Check NDC 67877-591-05 and lot numbers 21141321/21141322.
Ascend Laboratories recalls 50mg Metoprolol Succinate Extended-Release Tablets due to failed dissolution specification. This may affect medication effectiveness. Check NDC 67877-591-01 and lot 21142633 for affected products.
Ascend Laboratories recalls 25mg Metoprolol Succinate Extended-Release Tablets due to failed dissolution specification. This may affect medication effectiveness. Check NDC 67877-590-01 and lot numbers 21143094-21143121.
Ascend Laboratories recalls Rasagiline Mesylate 1mg tablets due to black spots or shiny metallic specks. This Rx-only medication was manufactured by Alkem in India and distributed in the US. Consumers should check their bottles for these spots and contact the company for details.
Ascend Laboratories recalls 25mg Metoprolol Succinate Extended-Release Tablets due to failed dissolution specifications. This may affect medication effectiveness. Check NDC 67877-590-01 and lot #21143093 for affected products.
Ascend Laboratories recalls 400mg Cefixime Capsules (Rx only) due to failed impurities/degradation specifications. Products manufactured by Alkem Laboratories Ltd. in Mumbai, India, with specific lot numbers and expiration dates.
Ascend Laboratories recalls 400mg Cefixime Capsules (50-count) due to potential impurities. Rx-only medication distributed in the US from 2014-02-08 to 2021-12-31. No specific remedy stated in recall notice.
